Context Therapeutics Inc. (CNTX)

Nasdaq Pharmaceutical Pharmaceutical Preparations SIC: 2834
D
Pipeline Grade

Financial Position (from SEC Filings)

$54.5M
Cash & Equivalents
$11.4M
Quarterly Burn Rate
14 mo
Est. Cash Runway
$274M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

No upcoming catalysts detected for this company.

Active Clinical Trials (2)

NCT #TitlePhaseStatusEnrollment
NCT04719273 Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer PHASE2 Active Not Recruiting 14
NCT06515613 A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors PHASE1 Recruiting 80

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for CNTX.

SEC EDGAR Filings

All SEC filings for Context Therapeutics Inc. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.